U.S. Senate Debates How to Lower High Drug Prices
U.S. Senate Debates How to Lower High Drug Prices
Senate has been actively debating how to lower high prescription drug prices, an issue that deeply affects millions of families.
A major milestone was the 2022 Inflation Reduction Act (IRA), which allowed Medicare to negotiate certain drug prices and capped insulin costs at $35 per month.
Lawmakers are currently scrutinizing Pharmacy Benefit Managers (PBMs)—the middlemen in the supply chain—who are accused of favoring expensive drugs to boost their own profits.
Another hot topic is "patent thickets," where companies use excessive patents to block cheaper generic alternatives from entering the market.
The core tension lies in balancing lower consumer costs with the need for pharmaceutical innovation.
While Democrats often support direct government regulation, Republicans tend to emphasize market-based competition and deregulation.
Despite these political differences, there is strong bipartisan agreement on one thing: the current system lacks transparency.
As Senate committees continue to hold hearings, the goal remains clear: making life-saving medications affordable without discouraging the research and development of future cures.
